Corbus Pharmaceuticals Q1 FY23 R&D Expenses Grow 307% To $13.4M

Corbus Pharmaceuticals Holdings, Inc. CRBP, a precision oncology company, released financial results for the first quarter of 2023.

Q1 2023 Financial Highlights

• The company reported a net loss of approximately $17.7 million, or a net loss per diluted share of $4.24, for the three months ended March 31, 2023, compared to a net loss of approximately $9.4 million, or a net loss per diluted share of $2.26, for the same period in 2022.

• Operating expenses increased by $8.8 million to approximately $17.3 million for the three months ended March 31, 2023, compared to $8.5 million in the comparable period in the prior year.

• As of March 31, 2023, the company has $44.2 million of cash and investments on hand which is expected to fund operations through the second quarter of 2024, based on the current planned expenditures.

"During our first quarter we continued our evolution into a precision oncology company, led by the execution of our exclusive licensing agreement for CRB-701, a next generation Nectin-4 ADC," stated Yuval Cohen, Ph.D., CEO of Corbus. "We are excited about the potential of this differentiated clinical stage asset that targets Nectin-4 enriched tumors. We also presented additional pre-clinical data at AACR 2023 annual meeting on CRB-601, demonstrating robust target engagement associated with anti-tumor activity alone and in combination with anti-PD-1. We believe this data reinforces the potential of this new approach in blocking activation of TGFβ locally in the TME. We look forward to advancing both CRB-701 and CRB-601 and potentially delivering on a number of milestones in 2023."

Photo by Louis Reed on Unsplash

Related News

Corbus Pharma Expands Precision Oncology Pipeline With Addition Of Clinical-Stage Antibody Drug Conjugate

Corbus In-Licenses Two Anti-Integrin Antibodies Targeting Cancer, Fibrotic Diseases Settings